Specialized Programs of Research Excellence (SPOREs) in Human Cancers (P50 Clinical Trial Required)
State‐of‐the‐art P50 center grants supporting integrated translational research in organ‐specific or theme‐based cancers. Each SPORE includes at least three projects (or two large projects at renewal), an Administrative Core, a Biospecimen Core, a Developmental Research Program, a Career Enhancement Program, and at least one investigator‐initiated clinical trial.
Eligibility Criteria:
-
U.S. applicant institutions (academic, nonprofit, for‐profit, or government).
-
PD/PI commitment of at least 2.4 person‐months (or at least 1.8 each if three or more PD/PIs).
-
Minimum of four investigators with active peer‐reviewed cancer grants or NCI trial leadership.
-
New applications: at least three translational projects with human endpoints (including at least one clinical trial).
-
Renewal applications: option for two large, multi‐institutional projects.
Funding Details:
-
Up to USD 1.4 million direct costs per year.
-
Additional USD 120 thousand per year for qualified Early Detection, Prevention, or Population Science (EPPS) projects.
-
Additional USD 120 thousand per year for qualified Cancer Health Disparities/Minority Health (CHD-MH) projects.
-
USD 50 thousand per year discretionary Administrative Core funds.
-
Support for SPORE-related investigator travel (up to ten investigators to NCI-sponsored meetings).
Deadlines:
-
Application due by 5 PM local time on September 25 2025.
-
Letter of Intent due 30 days before each application deadline.
Where to Apply & Contact:
-
Apply via NIH ASSIST.
-
Funding Opportunity PAR-23-284.
-
Program Director, NCI SPOREs: Igor Kuzmin, Ph.D. ([email protected]).
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023